drugset / Trial / NCT02839356

Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis

NCT02839356

Phase 4 Unknown 670 enrolled Anhui Provincial Hospital
RandomizedParallel-groupDouble-blindPrevention

Summary

Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) has been a well-recognized complication with significant morbidity and even mortality. A variety of possible mechanisms has been suggested in the occurrence of pancreatitis, but papillary edema caused by manipulations during cannulation or endoscopic treatment has received the most attention. The papillary edema may cause temporary outflow obstruction of pancreatic juice, and then increase ductal pressure, resulting in the occurrence of pancreatitis. Topical application of epinephrine on the papilla may reduce papillary edema. Moreover, it is reported that epinephrine sprayed on the papilla may be effective to prevent PEP. However, it is still unclear that epinephrine sprayed on the papilla can prevent acute pancreatitis after endoscopic retrograde cholangiopancreatography. We therefore designed a prospective randomized trial to determine whether epinephrine sprayed on the papilla prevent PEP after ERCP.

Timeline

Start
2016-07
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinephrine Other / unclassified 0.02 % Topical
Subject Epinephrine Other / unclassified 20 ml Topical

Indications